Clinical Trials Logo

Hepatopulmonary Syndrome clinical trials

View clinical trials related to Hepatopulmonary Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03600870 Completed - Clinical trials for Hepatopulmonary Syndrome (HPS)

Midodrine in Hepatopulmonary Syndrome

Start date: August 2, 2018
Phase: Phase 1
Study type: Interventional

This proof-of-concept clinical trial will determine the safety and tolerability of midodrine in patients with hepatopulmonary syndrome (HPS). Exploratory endpoints will assess the effect of midodrine on oxygenation, intrapulmonary shunting and symptoms.

NCT ID: NCT02148536 Completed - Clinical trials for Hepatopulmonary Syndrome

Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome

Start date: June 2014
Phase:
Study type: Observational

To prospectively investigate the effect of transjugular intrahepatic portosystemic shunt (TIPS) on oxygenation in cirrhotic patients with hepatopulmonary syndrome (HPS).

NCT ID: NCT00362752 Completed - Clinical trials for Hepatopulmonary Syndrome

A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The hepatopulmonary syndrome (HPS)and pre-HPS is a disease seen in patients with chronic liver disease, whereby patients develop dilations in the blood vessels of the lungs, resulting in low oxygen levels and shortness of breath. In this study, each HPS and pre-HPS subject will be treated with a commonly used antibiotic called "norfloxacin" (approved for use in the treatment of gonorrhea, prostatitis and urinary tract infections) for a 4-week period. In order to ensure that any observed improvement was indeed due to norfloxacin, each subject will also be treated with a separate 4-week course of an identical placebo. There will also be a 4 week wash-out period (no study medication/placebo) between the 2 courses of treatment. The primary aim of the study will be to measure improvements in oxygen levels while on norfloxacin, although a number of secondary parameters will also be followed.